{"organizations": [], "uuid": "754b176aa0bae900ed5afcd619445e38a3728e7e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.wsj.com", "main_image": "http://si.wsj.net/img/WSJ_Logo_black_social.gif", "site_section": "http://www.wsj.com/news/business", "section_title": "Business &amp; Finance News - Wall Street Journal", "url": "http://www.wsj.com/articles/new-novartis-heart-failure-drug-should-cost-17-less-research-group-says-1441987006", "country": "US", "title": "New Novartis Heart-Failure Drug Should Cost 17% Less, Research Group Says", "performance_score": 0, "site": "wsj.com", "participants_count": 1, "title_full": "New Novartis Heart-Failure Drug Should Cost 17% Less, Research Group Says - WSJ", "spam_score": 0.0, "site_type": "news", "published": "2015-09-11T19:56:00.000+03:00", "replies_count": 0, "uuid": "754b176aa0bae900ed5afcd619445e38a3728e7e"}, "author": "Peter Loftus", "url": "http://www.wsj.com/articles/new-novartis-heart-failure-drug-should-cost-17-less-research-group-says-1441987006", "ord_in_thread": 0, "title": "New Novartis Heart-Failure Drug Should Cost 17% Less, Research Group Says", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Novartis AG’s new heart-failure treatment should cost about 17% less than what Novartis is charging for it in the U.S. because expected wide use of the drug will strain health-care budgets, a nonprofit research group said Friday.\nEntresto’s U.S. list price, also known as its wholesale acquisition cost, is $12.50 a day, or about $4,560 a year per patient. Some analysts have estimated the drug could eventually generate more than $6... ", "external_links": [], "published": "2015-09-11T19:56:00.000+03:00", "crawled": "2015-09-11T20:17:36.748+03:00", "highlightTitle": ""}